Treace Announces Preliminary, Unaudited Fourth Quarter and Full-Year 2023 Revenue

January 8, 2024

https://www.globenewswire.com/news-release/2024/01/08/2805249/0/en/Treace-Announces-Preliminary-Unaudited-Fourth-Quarter-and-Full-Year-2023-Revenue.html

PONTE VEDRA, Fla., Jan. 08, 2024 (GLOBE NEWSWIRE) — Treace Medical Concepts, Inc. (“Treace” or the “Company”) (NasdaqGS: TMCI), a medical technology company driving a fundamental shift in the surgical treatment of bunions and related midfoot deformities through its flagship Lapiplasty® and Adductoplasty® Procedures, today announced its preliminary, unaudited fourth quarter and full-year 2023 revenue results.

Read more at globenewswire.com

Related news for (TMCI)

NASDAQ and NYSE quotes and data are delayed 15 minutes unless indicated otherwise. Market data and exchange information are provided for informational purposes only and is not intended for trading purposes. Neither 24/7 Market News Editors, 247 Market News, or data and content providers shall be liable for any errors or omissions, delays, misquotes or other market information relayed in any press materials. You should Use Realtime data to conduct due diligence before investing or trading, and trading in any stock is risky you could lose all your money.